The three approved injection sites for semaglutide Semaglutide is a subcutaneous injection
Lymphoedema (11%) and peripheral edema (11%) occurred in postmenopausal women with operable breast cancer who received adjuvant tamoxifen therapy (n = 3094) in the ATAC trial
Tao X, Zhang X, Ge SQ, Zhang EH, Zhang B
Discuss these risks with your provider
A taper reverses this ladder over a similar 20-to-24-week window: Weeks 1 to 4: reduce to 12.5 mg weekly Weeks 5 to 8: reduce to 10 mg weekly Weeks 9 to 12: reduce to 7.5 mg weekly Weeks 13 to 16: reduce to 5 mg weekly Weeks 17 to 20: reduce to 2.5 mg weekly Week 21: discontinue, or evaluate ongoing need at 2.5 mg The SURMOUNT-3 trial (N=579) showed that patients who completed an intensive lifestyle intervention before starting tirzepatide lost an additional 18.4% on-drug [9]
The cost difference is enormous (brand-name can exceed $1,000 per month without insurance), but so is the dosing safety margin